

Ascenta Therapeutics Hosts Shanghai Delegation During Visit to San Diego, California

SAN DIEGO, CA - April 11, 2006

Ascenta executives hosted a government and industry delegation from Shanghai, China during a recent tour and lecture series in San Diego. The group included Ms. Yuying Shang, Deputy Governor of Shanghai-Pudong District and Mr. Chengdong Yi, Director of the Shanghai office of the SFDA Chinese regulatory body, and Ms. Ningni Yu, Vice General Manager, Shanghai Zhangjiang Biotech & Pharmaceutical Base Development Co., Ltd., among other delegates from the region.

With its Ascenta Shanghai subsidiary in the Pudong District of Shanghai and relationships with many Chinese research institutions and commercial service providers, Ascenta is well poised to take advantage of the growing pharmaceutical sector in China.

"With the establishment of Ascenta Shanghai in 2005 and our collaboration with local research institutions and companies, Ascenta is looking forward to expanding our Shanghai facility and our circle of relationships in the region", said Dr. Jon T. Holmlund, Chief Medical Officer of Ascenta. "Ascenta Shanghai has been critical to our rapid development progress with AT-101, our lead Phase II clinical candidate", said Ascenta Shanghai General Manager Dr. Dajun Yang. "The Pudong district in Shanghai is home to research and development facilities of many of the leading pharmaceutical and biotechnology companies in the world, and we are in good company with our growing office and laboratory facilities in the Pudong Zhangjiang Hitech Park."

Founded in 2003, Ascenta is a privately-held biopharmaceutical company that discovers and develops targeted new medicines for the treatment of cancer. The company has offices in San Diego, California and a preclinical research facility in Shanghai, China. Its technology is focused on discovering molecules that hit vulnerable targets in endogenous apoptosis pathways and shut down cell growth and proliferation in cancer cells. Ascenta's broad pipeline of compounds is licensed from both the National Institutes of Health and the laboratory of Dr. Shaomeng Wang at the University of Michigan.